Chronological age measures time lived; biological age attempts to measure the accumulated molecular and physiological effects of genetics, lifestyle, metabolism, inflammation and disease. This distinction matters because two people of the same calendar age may have very different vascular function, myocardial reserve and future cardiovascular risk. The program is designed for research and longitudinal monitoring—not as a deterministic lifespan test.
Scientific interpretation framework
A clear framework helps visitors distinguish measurement, evidence and responsible translation into care or research.
Evidence level
Each finding is assessed against peer-reviewed literature, professional guidance, analytical validity and the maturity of clinical evidence. Research signals are identified explicitly and are not presented as established care.
Biological and clinical context
Molecular data are interpreted together with phenotype, family history, medicines, imaging, laboratory measurements and population context. No biomarker is meaningful in isolation.
Responsible output
Reports state the method, result, uncertainty, limitations and appropriate next step. Clinically relevant findings require qualified review; research models require validation before use in patient decisions.
DNA methylation clocks
Age-associated methylation patterns are combined into statistical clocks. Age acceleration—the difference between predicted and chronological age—has been associated with health outcomes, but estimates vary by tissue, platform, ancestry and algorithm.1
Inflammaging and cellular senescence
Chronic low-grade inflammation and senescent cells can alter vascular endothelium, extracellular matrix, immune function and metabolic signalling. Measuring these pathways may help identify mechanisms of accelerated cardiovascular ageing rather than merely restating calendar age.2
Telomere and proteomic context
Telomere length reflects one aspect of replicative history, while plasma proteins capture immune, extracellular-matrix, metabolic and organ-related processes. Large cohort studies show that proteomic age acceleration is associated with multimorbidity and cardiovascular outcomes, but population associations do not automatically establish individual clinical actionability.3
Why longitudinal measurement matters
A useful biological-age program should ask whether a molecular trajectory is stable, worsening or responsive to a defined intervention. Repeated measurements, standardized pre-analytics and comparison with blood pressure, lipids, glycaemia, imaging and established risk scores are more informative than a single uncontextualized number.3
Interpretation and limitations
No universal cardiovascular-age reference standard exists. Models may be population-specific and can be affected by acute illness, medication and technical batch effects. Results should therefore report uncertainty, the contributing biological domains and validation status—not only an attractive age estimate.3
A scientifically useful report
A responsible report identifies the clock or model, reference population, specimen, assay uncertainty and the biological domains driving the estimate. It presents trajectories and confidence intervals rather than a deterministic prediction of lifespan or a single consumer-facing age number.2
- Horvath, S. DNA methylation age of human tissues and cell types. Genome Biol. 14, R115 (2013). doi:10.1186/gb-2013-14-10-r115
- Argentieri, M. A. et al. Proteomic aging clock predicts mortality and risk of common age-related diseases in diverse populations. Nat. Med. 30, 2450–2460 (2024). doi:10.1038/s41591-024-03164-7
- Tanaka, T. et al. Plasma proteomic signature of age predicts health and life span. eLife 9, e61073 (2020). doi:10.7554/eLife.61073